2024
|
Invention
|
Novel rna construct and a method of preparing circular rna using the same. Provided is an RNA con... |
|
Invention
|
Cyclohexene derivative and pharmaceutical composition containing same. The present invention prov... |
|
Invention
|
Cyclohexene derivative and pharmaceutical composition comprising same. The present invention prov... |
|
Invention
|
3'-utr with improved translation efficiency, a synthetic nucleic acid molecule comprising the sam... |
|
Invention
|
Ionizable lipid and use thereof. The present invention relates to a novel ionizable lipid compoun... |
|
Invention
|
Ionizable lipids and uses thereof. The present invention relates to a novel ionizable lipid compo... |
|
Invention
|
Novel lyophilized formulation containing α-galactosidase a fusion protein. The present invention ... |
|
Invention
|
Composition for the treatment of sanfilippo syndrome type a (mps iiia) comprising heparan n-sulfa... |
|
Invention
|
5'-utr containing mrna constructs with improved translation efficiency and vaccine compositions c... |
|
Invention
|
Novel liquid formulation for prevention or treatment of thrombotic disease. The present invention... |
2023
|
Invention
|
Pharmaceutical composition comprising heparan n-sulfatase with improved stability. The present in... |
|
Invention
|
Composition for treating of facial dysmorphism in mucopolysaccharidosis.
A composition and a use... |
|
Invention
|
Cycloalkane-based lipid compound for delivering nucleic acids, and lipid nanoparticles comprising... |
|
Invention
|
Composition for treatment of facial dysmorphism in mucopolysaccharidosis. The present invention r... |
|
Invention
|
Pharmaceutical composition for preventing or treating hemarthrosis. The present invention relates... |
|
Invention
|
Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same. The... |
|
Invention
|
Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives. The present inventio... |
|
Invention
|
Novel process for purifying heparan-n-sulfatase. The present invention is related to a method for... |
|
Invention
|
Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery |
|
Invention
|
Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery. The ... |
|
Invention
|
Novel liquid formulation for plasma protein. The present invention relates to a pharmaceutical fo... |
|
Invention
|
Novel liquid formulation for lyophilization of plasma protein. The present invention relates to a... |
|
Invention
|
Liquid formulation comprising a fusion protein including a-galactosidase a.
The present inventio... |
|
Invention
|
Lyophilized formulation comprising a fusion protein including a-galactosidase a.
The present inv... |
|
Invention
|
Lyophilized formulation comprising a fusion protein including α-galactosidase a |
|
Invention
|
Lyophilized formulation comprising a fusion protein including α-galactosidase a. The present inve... |
|
Invention
|
Liquid formulation comprising a fusion protein including α-galactosidase a |
|
Invention
|
Liquid formulation comprising a fusion protein including α-galactosidase a. The present invention... |
|
Invention
|
Method for purifying factor xiii. Disclosed is a method of purifying factor XIII comprising (a) f... |
2022
|
Invention
|
Method for preventing or treating of hemathrosis.
A pharmaceutical composition capable of exhibi... |
|
Invention
|
5'-utr with improved translation efficiency, a synthetic nucleic acid molecule including the same... |
|
Invention
|
Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same.
An anti-C... |
|
Invention
|
Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically ... |
|
Invention
|
A composition for treatment of hepatitis b comprising hbv specific antibody for combination with ... |
|
Invention
|
Method for purification of hemopexin and haptoglobin.
The present invention relates to a method ... |
2021
|
Invention
|
Self-administration assistance device. The present invention relates to a self-administration ass... |
|
Invention
|
Coronavirus spike protein-specific antibody and use thereof.
Provided are a coronavirus spike (S... |
|
Invention
|
Adamts13 variant having increased escaping rate or activity against autoantibody.
An ADAMTS13 mu... |
|
Invention
|
Adamts13 variant having increased escaping rate or activity against autoantibody. The present inv... |
|
Invention
|
Method for production of varicella zoster virus surface protein antigen.
A method for production... |
2020
|
Invention
|
Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically... |
|
Invention
|
Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceuticall... |
|
Invention
|
Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt... |
2019
|
Invention
|
Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bisp... |
|
P/S
|
Pharmaceuticals; drugs for medical purposes; medicines for
human purposes; human vaccine prepara... |
|
Invention
|
Steric epitope of ceacam1, and anti-ceacam1 antibody, or fragment thereof, that specifically bind... |
|
P/S
|
Pharmaceutical agents affecting metabolism for liver
disease; biological preparations for liver ... |
2017
|
P/S
|
Medicines for mucopolysaccharidoses; medicines for treating metabolism disorder; bacteriological ... |
|
P/S
|
Medicines for human purposes; pharmaceutical preparations. |
|
P/S
|
Pharmaceutical preparations for central nerve treatment;
pharmaceutical preparations for diagnos... |
2016
|
P/S
|
Medicines for mucopolysaccharidoses; medicines for treating metabolism disorder, namely diabetes,... |
|
P/S
|
Medicines for mucopolysaccharidoses; medicines for treating
metabolism disorder; bacteriological... |
|
P/S
|
Pharmaceuticals; pharmaceutical preparations for the
treatment of neutropenia; pharmaceutical pr... |
|
P/S
|
Pharmaceutical preparations for the treatment of hemophilia;
vial preparations for the treatment... |
2015
|
P/S
|
Pharmaceutical preparations, namely, Intravenous immunoglobulin (IVIG) |